X
66.04
-2.22 (-3.25%)
| Previous Close | 68.26 |
| Open | 68.16 |
| Volume | 695,684 |
| Avg. Volume (3M) | 1,446,813 |
| Market Cap | 6,383,793,152 |
| Price / Sales | 591.55 |
| Price / Book | 4.93 |
| 52 Weeks Range |
| Operating Margin (TTM) | -969.84% |
| Diluted EPS (TTM) | -3.22 |
| Total Debt/Equity (MRQ) | 1.23% |
| Current Ratio (MRQ) | 17.66 |
| Operating Cash Flow (TTM) | -196.85 M |
| Levered Free Cash Flow (TTM) | -128.49 M |
| Return on Assets (TTM) | -22.03% |
| Return on Equity (TTM) | -31.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Xenon Pharmaceuticals Inc. | Mixed | Bullish |
AIStockmoo Score
0.3
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.33 |
|
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.14% |
| % Held by Institutions | 103.51% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |